TY  - JOUR
T1  - Recent Updates regarding Atrial Fibrillation and Thromboembolism Diagnosis and Management Approach
A1  - Hawra M. Alismail
A1  - Asma M. Asiri
A1  - Hassan A. Alomran
A1  - Osama A. Almohammedsaleh
A1  - Zainab A A Slais
A1  - Mubarak M. Aldosari
A1  - Fahad M. Albaiji
A1  - Bayan A. Alzain
A1  - Sara S. Al Tukruni
A1  - Assem O. Alhazmi
JF  - Pharmacophore
JO  - Pharmacophore
SN  - 2229-5402
Y1  - 2020
VL  - 11
IS  - 5
SP  - 145
EP  - 150
N2  - Background: Atrial Fibrillation is a dysregulation of a cardiac rhythm resulting in the irregularity of the atrial contraction. This dysregulation causes an increase in atrial rate between 300 to 600 bpm. Atrial Fibrillation (AF) accounts for an increasing healthcare system burden worldwide in regards to disability and economic status. AF-related morbidities include stroke, heart failure, cardiovascular death, and a profound decrease in life quality. Objective: In this review paper we aimed to give an overview of AF, predisposing factors, and the potential consequences. Additionally, the management options in treating and preventing AF-related complications, particularly ischemic stroke. Methodology: We used the PubMed database and searched for 18 relative articles, using two Mesh terms: "Atrial Fibrillation" and "Thromboembolism." Conclusion: Ischemic stroke and thromboembolism account for a significant burden to the healthcare system globally. Treating AF, and more importantly, preventing thromboembolic events can markedly reduce this burden and improve the life quality of patients. Management includes pharmacological and non-pharmacological, and choosing one of them is based on the patient eligibility and risk of bleeding
UR  - https://pharmacophorejournal.com/article/atrial-fibrillation-and-thromboembolism-overview-and-management
ER  -